Previous Close | 2.5800 |
Open | 2.5800 |
Bid | 2.6100 x N/A |
Ask | 2.6200 x N/A |
Day's Range | 2.5300 - 2.6300 |
52 Week Range | 1.4400 - 3.1600 |
Volume | |
Avg. Volume | 28,350 |
Market Cap | 64.343M |
Beta (5Y Monthly) | 1.95 |
PE Ratio (TTM) | 20.08 |
EPS (TTM) | 0.1300 |
Earnings Date | Nov 07, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.44 |
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to publicly funded drug programs and patients in Canada. The pCPA is an independent organization whose membership includes the provincial, territorial, and federal governments.Reaching this
Investors were disappointed with the weak earnings posted by Medexus Pharmaceuticals Inc. ( TSE:MDP ). However, our...